Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 10/20 | 0.42 |
| ▸ | PPARG | P37231 | 8/20 | 0.42 |
| ▸ | PPARD | Q03181 | 2/20 | 0.39 |
| ▸ | XDH | P47989 | 2/20 | 0.38 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.38 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4339362 | 1.00 | PPARA (0.42) | PPARAPPARGPPARDXDHSLC22A12 | |
| SCHEMBL4327670 | 1.00 | PPARA (0.42) | PPARAPPARGPPARDXDHSLC22A12 | |
| SCHEMBL27705612 | 0.93 | PPARA (0.37) | PPARAPPARGXDHSLC22A12MRGPRX4 | |
| Water SCHEMBL2865400 | 0.93 | PPARA (0.37) | PPARAPPARGXDHSLC22A12MRGPRX4 | |
| SCHEMBL2859483 | 0.93 | PPARA (0.37) | PPARAPPARGXDHSLC22A12MRGPRX4 | |
| Water SCHEMBL2868338 | 0.93 | PPARA (0.37) | PPARAPPARGXDHSLC22A12MRGPRX4 | |
| SCHEMBL6014012 | 0.93 | PPARA (0.37) | PPARAPPARGXDHSLC22A12MRGPRX4 | |
| SCHEMBL13810963 | 0.93 | XDH (0.38) | PPARAPPARGXDHSLC22A12MRGPRX4 | |
| SCHEMBL4330032 | 0.92 | PPARA (0.42) | PPARAPPARGPPARDXDHSLC22A12 | |
| SCHEMBL2867578 | 0.92 | PPARA (0.42) | PPARAPPARGPPARDXDHSLC22A12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7544835-B2 | Carboxylic acid derivative and salt thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-06-09 | — | — | US | claimed |
| US-20060177444-A1 | Concomitant drug as therapeutic agent for inflammatory bowel disease | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2006-08-10 | — | — | US | claimed |
| EP-1607103-A1 | CONCOMITANT DRUG AS THERAPEUTIC AGENT FOR INFLAMMATORY BOWEL DISEASE | Eisai Co., Ltd. (JP) | 2005-12-21 | — | — | EP | claimed |
| US-20040102634-A1 | Carboxylic acid derivative and salt thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2004-05-27 | — | — | US | claimed |
| EP-1380562-A1 | CARBOXYLIC ACID DERIVATIVE AND SALT THEREOF | Eisai Co., Ltd. (JP) | 2004-01-14 | — | — | EP | claimed |
| WO-2017044551-A1 | PPAR-ALPHA AGONISTS FOR TREATING MITOCHONDRIAL DISEASES | MITOBRIDGE, INC. (US) | 2017-03-16 | — | — | WO | disclosed |
| US-7816405-B2 | Calcium bis [(2S)-3-[3-[(2S)-3-(4-chloro-2-cyanophenoxy)-2-fluoropropoxy]phenyl ]-2-isopropoxypropionate] and intermediate thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-10-19 | — | — | US | disclosed |
| US-7816405-B2 | Calcium bis [(2S)-3-[3-[(2S)-3-(4-chloro-2-cyanophenoxy)-2-fluoropropoxy]phenyl ]-2-isopropoxypropionate] and intermediate thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-10-19 | — | — | US | disclosed |
| US-7816405-B2 | Calcium bis [(2S)-3-[3-[(2S)-3-(4-chloro-2-cyanophenoxy)-2-fluoropropoxy]phenyl ]-2-isopropoxypropionate] and intermediate thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-10-19 | — | — | US | disclosed |
| US-7816405-B2 | Calcium bis [(2S)-3-[3-[(2S)-3-(4-chloro-2-cyanophenoxy)-2-fluoropropoxy]phenyl ]-2-isopropoxypropionate] and intermediate thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-10-19 | — | — | US | disclosed |
| US-7816405-B2 | Calcium bis [(2S)-3-[3-[(2S)-3-(4-chloro-2-cyanophenoxy)-2-fluoropropoxy]phenyl ]-2-isopropoxypropionate] and intermediate thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-10-19 | — | — | US | disclosed |
| US-7544835-B2 | Carboxylic acid derivative and salt thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-06-09 | — | — | US | disclosed |
| US-20070117866-A1 | Calcium bis [ (2S) - 3- [3-[ (2S) -3- (4-chloro-2-cyanophenoxy) -2- fluoropropoxy]phenyl ]-2-isopropoxypropionate] and intermediate thereof | EISAI CO., LTD. (JP) | 2007-05-24 | — | — | US | disclosed |
| US-20070117866-A1 | Calcium bis [ (2S) - 3- [3-[ (2S) -3- (4-chloro-2-cyanophenoxy) -2- fluoropropoxy]phenyl ]-2-isopropoxypropionate] and intermediate thereof | EISAI CO., LTD. (JP) | 2007-05-24 | — | — | US | disclosed |
| US-20070117866-A1 | Calcium bis [ (2S) - 3- [3-[ (2S) -3- (4-chloro-2-cyanophenoxy) -2- fluoropropoxy]phenyl ]-2-isopropoxypropionate] and intermediate thereof | EISAI CO., LTD. (JP) | 2007-05-24 | — | — | US | disclosed |
| US-20070117866-A1 | Calcium bis [ (2S) - 3- [3-[ (2S) -3- (4-chloro-2-cyanophenoxy) -2- fluoropropoxy]phenyl ]-2-isopropoxypropionate] and intermediate thereof | EISAI CO., LTD. (JP) | 2007-05-24 | — | — | US | disclosed |
| US-20060177444-A1 | Concomitant drug as therapeutic agent for inflammatory bowel disease | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2006-08-10 | — | — | US | disclosed |
| EP-1607103-A1 | CONCOMITANT DRUG AS THERAPEUTIC AGENT FOR INFLAMMATORY BOWEL DISEASE | Eisai Co., Ltd. (JP) | 2005-12-21 | — | — | EP | disclosed |
| US-20040102634-A1 | Carboxylic acid derivative and salt thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2004-05-27 | — | — | US | disclosed |
| EP-1380562-A1 | CARBOXYLIC ACID DERIVATIVE AND SALT THEREOF | Eisai Co., Ltd. (JP) | 2004-01-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040102634-A1 | Carboxylic acid derivative and salt thereof | GPR119, IRS1, SLC5A1 | PPARA 339/4885PPARG 379/4885PPARD 753/4885 |
| US-20060177444-A1 | Concomitant drug as therapeutic agent for inflammatory bowel disease | PPARG, PPARA, NR3C1 | PPARA 2/4885PPARG 1/4885PPARD 4/4885 |
| US-20070117866-A1 | Calcium bis [ (2S) - 3- [3-[ (2S) -3- (4-chloro-2-cyanophenoxy) -2- fluoropropoxy]phenyl ]-2-isopropoxypropionate] and intermediate thereof | CA2, CACNA1A, CACNA1C | PPARA 3168/4885PPARG 3388/4885PPARD 3087/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.